- Home
- JHI vs CNTB Comparison
JHI vs CNTB Comparison
Compare JHI & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JHI | CNTB |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 135.7M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JHI | CNTB |
|---|---|---|
| Price | $13.23 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 12.1K | ★ 287.7K |
| Earning Date | 01-01-0001 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.50 | $1.23 |
| 52 Week High | $14.51 | $3.82 |
Technical Indicators
Market Signals| Indicator | JHI | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 53.42 |
| Support Level | $13.24 | $2.03 |
| Resistance Level | $13.56 | $2.68 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 73.59 | 89.74 |
Price Performance
Historical ComparisonAbout JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others. The company's portfolio includes Corporate Bonds, Term Loans, U.S Government Agency, and Others.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.